Carrier's Pricing Strategy Evolution Amid Inflation Pressures Q1 2026

Key factors driving Jazz Pharmaceuticals’ Q1 2026 revenue growth

1) Broad-based commercial execution across the core franchise

Jazz reported highest-ever first quarter total revenues of $1.1 billion, reflecting more than 19% year-over-year growth, driven by the performance of Xywav, Epidiolex, Midevo, and Zepzelca. ¹
Management also emphasized double-digit growth across all promoted brands and contributions from ongoing launches. ¹

2) Xywav: strong demand supported by both volume growth and modest timing effects

For Xywav, Q1 results reflected $408 million net product sales, up 18% year-over-year, supported by demand drivers and patient growth. ²
Jazz attributed the underlying performance to continued patient and HCP demand, including ~425 net patient adds and approximately 16,600 active patients. ²
On volume specifically, management said volume growth was about 12% in Q1. ³
Additionally, there was a temporary “net price pickup” in the quarter (linked to gross-to-net favorability and patients transitioning more quickly back to insurance during the reauthorization period), and management explicitly said this was a first-quarter phenomenon and not expected to repeat quarter-over-quarter in Q2–Q4. ³

Bottom line for growth contribution: Xywav’s Q1 growth was powered mainly by volume growth and patient adds, with some one-quarter net price favorability as a contributing tailwind. ²³

3) Epidiolex: growth driven by volume and persistency support

Epidiolex net product sales rose 15% to $250 million in Q1, with growth driven by strong underlying demand and 16% volume growth. ²
Management also highlighted the nurse navigator program as supporting patient persistency, and described a priority to expand utilization of that resource in 2026. ²
They also pointed to JazzCares support as a mechanism that can help patients stay on treatment longer. ⁴

Bottom line for growth contribution: Epidiolex growth appears tied to utilization/persistency programs and volume expansion rather than reliance on timing mechanics. ²⁴

4) Midevo: early launch momentum with meaningful sales and treated-patient scale

Jazz’s Q1 results included Midevo as a named driver of top-line growth, and management later clarified its launch progress. ¹
Midevo generated $41 million in Q1 net product sales, and management expressed confidence around reaching a $500 million peak opportunity in the U.S. ⁵
They also stated ~500 patients had been treated since launch through the end of Q1, reflecting strong launch uptake supported by high awareness (physicians + advocacy) and patient advocacy. ⁵
In addition, management said patients are staying on treatment longer than initially anticipated, but noted they need cohort maturity to quantify whether duration exceeds trial duration (around ten months). ⁵

Bottom line for growth contribution: Midevo contributed via early adoption scale (~500 treated) and management’s confidence tied to treatment duration/patient flow characteristics. ⁵

5) Zepzelca: accelerated growth tied to uptake in a new frontline maintenance setting

Zepzelca net product sales increased 60% to $101 million in Q1 versus the same period in 2025. ⁶
Management attributed the growth to strong uptake in frontline maintenance, following FDA approval of Zepzelca in combination with Tecentriq in October (for the 2025–2026 transition). ⁶
They linked rapid adoption to AMPHORA data and positioned that new indication as driving performance. ⁶

Bottom line for growth contribution: Zepzelca’s growth was heavily driven by new-label adoption (frontline maintenance) and provider uptake. ⁶

---

Other quantified factors that affected Q1 growth (timing + FX)

Shipping calendar effect

Jazz noted normal thirteen shipping weeks for its U.S. oncology products in Q1, versus twelve shipping weeks in the prior-year quarter, contributing about two percentage points to worldwide revenue growth. ⁷

Foreign exchange (FX)

Jazz also stated that significant devaluation of the U.S. dollar contributed about one and a half percentage points to worldwide revenue growth. ⁷

Bottom line for growth contribution: Beyond product demand, reported growth was boosted by (i) shipping-week timing and (ii) FX translation effects. ⁷

---

How guidance changed (and what did not)

Revenue guidance: reaffirmed

Jazz said it is reaffirming full-year 2026 revenue and expense guidance, including total revenue guidance of $4.25 billion to $4.5 billion. ⁸
They further stated they are on track to achieve that guidance based on Q1 performance. ⁸

Xywav competitive/generic assumptions: guidance framework unchanged

In that same guidance discussion, Jazz reiterated specific assumptions that generics in sleep are expected to increase competitive pressure in 2H (including high-sodium generics gaining volume and potential daytime wake-promoting agents entering narcolepsy), plus expected declines in Xyrem and high-sodium authorized generics as generics build volumes. ⁸
It also reiterated expectations for decline in second-line use of Zepzelca. ⁸

Conclusion on guidance change: Based on the excerpts, there was no upward or downward change to full-year 2026 revenue guidance; management instead reaffirmed the range ($4.25B–$4.5B). ⁸

One notable clarification (not a formal guidance change): Xywav quarter-to-quarter net price timing

While not described as an official change, management clarified that part of Xywav’s Q1 strength included a first-quarter net price pickup mechanism that they would not expect to see again in Q2–Q4. ³
This is important for interpreting why Q1 was strong without necessarily implying continued similar magnitude of sequential “pricing/timing” tailwinds. ³

---

Synthesis: what really drove Q1 growth and what to watch in the guidance outlook

• Primary growth engine: operational execution and volume/demand strength across the commercial portfolio—especially Xywav (18% sales growth, 12% volume growth, 425 net patient adds), Epidiolex (15% sales growth, 16% volume growth), plus Midevo ($41M, ~500 treated) and Zepzelca (60% sales growth driven by frontline maintenance adoption). ²⁵⁶³
• Reported growth “amplifiers”: shipping calendar (+~2 pp) and FX (+~1.5 pp). ⁷
• Guidance: full-year 2026 revenue guidance was reaffirmed at $4.25B–$4.5B (no change indicated in the excerpts). ⁸
• Near-term risk framing (within guidance assumptions): increased competitive dynamics in sleep in the second half (including generics and potential wake-promoting agents) and expected declines in certain therapies/segments. ⁸

Overall, the excerpts support a view that Q1 outperformance was mainly fundamentals-led (demand, volume, launch penetration, and new-indication adoption) with a secondary contribution from calendar/FX, while guidance remained steady despite acknowledging expected 2H competitive pressure. ²⁷⁸⁶